want to know more?
+31 (0)20 303 1970

UbiQ-news: Reagents for your SARS-CoV-2 research

By

Farid El Oualid

 


 
7 April 2021
Reagents for your SARS-CoV-2 research 

The SARS-CoV-2 coronavirus encodes a papain-like cysteine protease PLpro (NSP3) that cleaves the viral polyprotein, removes ubiquitin-like ISG15 protein modifications and (with lower activity) Lys48-linked polyubiquitin chains. As PLPro is essential for SARS-CoV-2 replication, it represents a promising target for the development of antiviral drugs. In light of this and to complement our well-known ubiquitin based reagents, we are expanding our portfolio of ISG15 based reagents. Recently we developed the fluorescence polarization assay reagent UbiQ-287 (short name hISG15 FP). This is based on full-length human ISG15 that is linked via an isopeptide bond to a 5-carboxytetramethylrhodamine (TAMRA, exc/emi 550/590 nm) functionalized dipeptide (Figure 1).
Figure 1. Human ISG15 FP reagent UbiQ-287.

Below we have listed our current portfolio of ISG15 based reagents.
 
UbiQ-073: ISG15 FP (activity assay reagent, mouse full-length)
UbiQ-287: hISG15 FP (activity assay reagent, human full-length)
UbiQ-127: Ac-ISG15prox-Rh110MP (activity assay reagent, mouse C-terminal domain)
UbiQ-262: Ac-ISG15prox-VPS (activity-based probe, mouse C-terminal domain)


 
 
contact UbiQ
 
 
LinkedIn LinkedIn
Twitter Twitter
Website Website
researchgate researchgate